Overall, the OT mini-classifier outperformed the BRAF/KRAS/NRAS status in predicting cetuximab response, despite inherent differences between datasets including patients from different populations and ethnic origins (US, European and Chinese), tumour stages and methodologies (microarrays versus RNAseq). The gene discussed is KRAS; the disease is neoplasm.